<DOC>
	<DOCNO>NCT00615264</DOCNO>
	<brief_summary>The purpose study determine DiaPep277 effectively protect internal production insulin patient newly diagnose type 1 diabetes , stop immune destruction insulin-producing beta-cells pancreas . DiaPep277 act immune system expect prevent destruction beta-cells stimulate regulatory response , without cause immunological suppression .</brief_summary>
	<brief_title>Efficacy Study DiaPep277 Newly Diagnosed Type 1 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>A diagnosis type 1 diabetes 3 month screen Insulin dependency Fasting Cpeptide level &gt; = 0.22 nmol/L Presence least 1 diabetesrelated autoantibody ( IA2A , GAD IA ) Pregnancy intent conceive next 2 year Significant disease could affect response treatment , tumor , psychiatric disorder , substance abuse , severe allergy diabetesrelated complication . Patient immune deficiency receives immunosuppressive cytotoxic drug .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>